Day 2 - ET (Eastern Time, GMT-05:00)
Day 2 - ET (Eastern Time, GMT-05:00)
- Katelyn Reichheld - Conference Producer, Informa Connect
- Hannah Putnam - Senior Director, Ethics & Compliance, Veloxis Pharmaceuticals
- Addressing live and pre-conference anonymous questions from industry
- Forecasting new regulations and guidance
- The future of offering meals and live programs
- Review the March 2023 updates of the DOJ Criminal Division Evaluation of Corporate Compliance Programs
- Jason Gould - Chief, Health Care Fraud Unit, United States Attorney's Office, District of New Jersey
- Charlene Keller Fullmer - Assistant U.S. Attorney & Deputy Chief & Affirmative Litigation, US Attorney’s Office Eastern District of Pennsylvania
- George Karavetsos - Shareholder, White Collar Defense, Compliance, and Investigations Practice Group Leader, Buchanan
- Unique challenges of pharma companies varying in size in what regulations they must adhere to
- Difference in approach to speaker programs based on size
- How to ensure the appropriate level of training and communication organization-wide
- When small-to-mid pharma grows quickly internally, how do they meet market needs?
- How can smaller companies react faster to constant changes in market or field needs year over year?
- Size perspective on live, virtual and hybrid meetings
- Context from mid-size pharma on how to manage resources and budget
- How do you create efficiencies on overlapping roles without burning out employees?
- Marianne Slivkova - Assistant General Counsel, Stemline Therapeutics
- Hannah Putnam - Senior Director, Ethics & Compliance, Veloxis Pharmaceuticals
- Stephanie Loiseau - Head of Marketing, SK Life Science
- Kimberly Coleman Clotman - Senior Director, Marketing Enablement Lead, Specialty, Pfizer
- David Caponera - Executive Director, Patient Advocacy, Communication, Public Affairs, and Sustainability, Novo Nordisk
- How to encourage your reps to fully utilize speakers
- How to manage expectations for the delivery time of speaker selections and streamline from a compliance and operational standpoint
- What is the accepted process for initiating the contracting of a speaker?
- Who nominates speakers for your bureau and how are KOLs selected?
- How many KOLs should be nominated to optimize utilization and relationship management
- Long term tracking of this process for future recall e.g. adding a speaker that was removed in prior years
- What are the attributes used to Tier Speakers for payment
- Role of Medical, Marketing, and the Sales organization on speaker nomination, selection, and utilization
- How do you address speaker needs when many KOLs can not, or will not participate on Speaker Bureaus?
- Karen Lowney - Head of the Office of Ethics & Compliance (OEC), Sun Pharmaceutical Industries, Taro Pharmaceutical Industries
- Kevin Verbosh - Corporate Compliance Leader, Spark Therapeutics
- How to organize attendee list, invitations and track registrations
- Bringing awareness of this issue to reps before programs and addressing with collaborating
- Mobilizing systems to input attendance before a program and crosschecking instantly
- Approaches to maximize program attendance with the right audience
- Scott Witherington - Director of Ethics & Compliance Risk Management & Business Partner, Novo Nordisk
- Stephanie Macholtz - Vice President, Healthcare Compliance, Organogenesis
- Speaker bureau establishment and maintenance
- Use of tech speakers and attendee reminders
- Ideal delivery timing, messaging and mode for safety information and program logistics
- Attendee self-registration – benefits and utilization
- Benchmark on who is employing pre and post learning evaluations, how they are being deployed, how to implement them
- Future of metrics and analytics backed programs – how to capture data needed to justify speaker programs
- Tech solution review for survey automation and enhancements
- Example questions to evaluate speaker and program attendee feedback
- How do you use Representative feedback on the program and speaker to inform future decisions?
- Teresa Hurlbut - Senior Manager, Event Operations, Blueprint Medicines
- Graham Brown - Associate Director US Compliance, argenx
- Case study on an agency/manufacturer partnership that led to the creation of engaging educational content
- How do companies build content, what do they utilize and why?
- When is it appropriate to have different decks for different speakers?
- Storytelling through content and form
- Personalization for speaker
- Diane Evans - Associate Director, Peer to Peer Marketing, Immunology, AbbVie
- Leveraging the way adults learn to enhance HCP learning and patient outcomes
- Taking traditional to the next level with technology and gaming neuroscience
- Maximizing new-normals in virtual/hybrid engagement for efficiencies and impact in speaker programming
- Legal framework to work within when creating stand out programs
- Trish Hanrahan - Senior Manager, Commercial Learning & Development, Sumitomo Pharma America
- Best practices for developing and rolling out monitoring and auditing programs
- Effective communication and partnership with sales leadership
- Industry standards for speaker program monitoring
- Monitoring virtual speaker programs
- Preparing a documented plan on which programs to monitor and audit, how many, which types, consistencies between speech and slide deck, etc.
- Learn what speaker programs data and metrics to arm leaders and the field with
- How to train, manage, and communicate with external consultants in addition to internal consultants
- Continuously improving the monitoring plan
- Audrey Caporaletti - Senior Compliance Manager, Teva Pharmaceuticals
- Jessica Constant - Associate Director, Commercial Excellence, Business Controls, AstraZeneca
- Kays Sawaged - Former Head of Compliance & Ethics, .
Do you struggle to justify the cost of your speaker programs? Do your sessions seem to be under-attended, or perhaps you question whether the desired attendees are joining? If so, join ZS as we discuss how the power of AI can help increase the effectiveness of your speaker programs. In this session, you will learn how companies are:
- Using real world data and AI/ML to optimize their speaker programs
- How to recruit best speakers
- How to ensure the right attendees are invited
- How data-driven insights can help to adhere to compliance guidelines
- How to design optimal annual program strategy to achieve desired outcome
- How to measure impact of speaker programs in compliant way
- Vendor ideas for on demand peer to peer programs
- How to use engagement tools in different ways
- How to keep materials as living resources instead of lackluster videos
- Tips for how to work with and onboard an agency partner and collaborate
- Holistic view of what a successful partnership and program looks like, policy and relationship with compliance
Join an esteemed panel of ethics and compliance veterans as they discuss the principles of FMV and the pitfalls of HCP compensation. Learn about rate construction in both common and emerging situations, such as influencer remuneration. Compare various approaches to speaker tours/multi-program speakers, virtual programs and local travel in a post-virtual world. Finally, hear a discussion about transparency with HCPs on rate construction, data monitoring and reevaluation.
- Eric Bolesh - Chief Operating Officer, Cutting Edge Information
- Daryl Kreml - Senior Vice President, Chief Compliance and Risk Officer, Sage Therapeutics
- Karen Lowney - Head of the Office of Ethics & Compliance (OEC), Sun Pharmaceutical Industries, Taro Pharmaceutical Industries
- Hannah Putnam - Senior Director, Ethics & Compliance, Veloxis Pharmaceuticals
This session will not be recorded or live streamed.
- Balancing the priority of diversity internally and in creation of speaker bureaus
- Create a plan of action plan to take back to your organization
- Supporting diversity within your business model
- How do you build a business model that builds DEI as a bottom-line principle
- How to connect intention to action in a meaningful way that demonstrates the symbiotic relationship between industry and consumer
Product Theater: also known as an Innovation Theater or symposium. These are Speaker Programs held at a conference organized by a third-party.
- Do you define a Product Theater differently than a traditional speaker program?
- What are considerations for nuanced guardrails given the circumstances of these events (e.g., no control of venue and attendance, PhRMA code requirements)?
- What are considerations for operationalizing nuanced controls?
- Validating legitimacy of the third-party event
- RSVP tracking
- Attendance tracking
- If invitations may be distributed by the company
- If and how meals may be funded or provided by the company
- Speaker selection
- Karalyn Cairns - Enterprise Compliance Manager, Strategic & Executional Excellence, AbbVie
- Vicki Montez - Senior Analyst, Peer to Peer Education, AbbVie